Jorge is the President of Vectura Fertin Pharma. He has spent over two decades in drug development in various areas such as immunology, neurology, cardiovascular, and analgesia, holding senior positions at Novartis, Bristol Myers Squibb and Sanofi. Jorge has directed the development of numerous innovative breakthrough medicines in immunology, neurology, cardiovascular and metabolism, oncology, ophthalmology, and rare diseases. He received his M.D. from Université de Paris and began his career as a hospital cardiologist in France.

Sylvie is the Global Head People and Culture for Vectura Fertin Pharma and is based in Switzerland. She has held senior HR roles focusing on recruitment, organizational design, and change management at Michelin, Novartis, Genentech/Roche, McKesson, and Philip Morris International. She has lived and worked in Asia, America, and Europe and has a strategic knowledge of the entire pharmaceutical business value chain through her experience supporting research, development, manufacturing, and distribution. 

Sylvain has 20+ experience in the Finance sector and serves Vectura Fertin Pharma as Chief Financial Officer. He spent 14 years at Novartis, holding senior leadership roles in the pharmaceutical business, most recently as Chief Financial Officer Europe and Global Head Business Planning for Novartis Research, prior to joining Philip Morris International in December 2021. Sylvain started his career in 2002 as a financial auditor with Arthur Andersen and subsequently joined Ernst & Young and KPMG. Sylvain studied finance and economics, received his MBA from INSEAD, and is a certified public accountant.

Kim is the Chief Consumer Health Officer, responsible for building our branded consumer health business. Kim holds a PhD in biochemistry from Michigan State University and an MBA from London Business School. Before joining Vectura Fertin Pharma, he worked for over 15 years in the specialty ingredients B2B industry. Previously, he was a management consultant at Boston Consulting Group. 

With 35 years of experience in the Pharma, Biotech, Life Sciences and Diagnostics industries, Annika is well positioned to articulate the vision, define the strategy, build the capabilities, and develop the processes to ensure we guarantee our quality commitment to our external stakeholders and consumers, across our key product categories.

Begoña leads all of our BD&L efforts, including External Innovation, Search & Evaluation, Negotiations, Due Diligence and Alliance Management. Begoña joined from Novartis Pharma, where she held the role of Worldwide Head BD&L of the Opthalmology Franchise. Over the last 16 years she has built a proven track record in licensing deals and M&A. She holds a PhD in Drug Delivery from the London School of Pharmacy, a 3-year Postdoctoral Research fellowship at the Centre for Polymer Therapeutics (London School of Pharmacy) and a BSc in Biochemistry from Keele University. 

Lesley is responsible for the development and implementation of Vectura Fertin Pharma’s global communications strategy, managing programs to promote, enhance and protect the company’s reputation and ensure strong, positive engagement with employees and external stakeholders. She is based in the UK. She has over 20 years’ experience in leading and building communications functions across multiple industries and companies, including at Mundipharma, Syngenta GE Healthcare and AstraZeneca. Her earlier career saw her working in industries ranging from energy and technology to media and public healthcare. Lesley holds a Bachelor of Honors in Philosophy from the University of Birmingham, UK.

Peter leads the emerging categories and the overall CDMO business for Vectura Fertin Pharma. Peter will continue as CEO at Fertin Pharma, which he joined in 2020, leading the business through its sale to Philip Morris International in 2021. Prior to joining Fertin Pharma, he held several international senior executive and executive roles with Doehler Group GmbH, Ingredion Inc., and Novozymes A/S. 

Klaus has over 19 years of experience within the healthcare industry, serving in various leadership roles across the pharma and medtech sectors. Klaus holds a Bachelors in Biophysics from the Niels Bohr Institute and a M.D. from the Panum Institute, both departments at the University of Copenhagen. He also holds a Graduate Diploma in Economics and Business Administration and an Executive MBA from Copenhagen Business School. In his role as Chief Medical Officer, Klaus will lead the creation and implementation of the development plan for the global programmes, and will define and execute Vectura Fertin Pharma’s clinical, medical, and regulatory strategies.

Julia has extensive expertise in establishing external innovation strategies and programs within the life science sector to develop products, technologies, and partnerships that advance business objectives. Julia leads the external innovation team for Vectura Fertin Pharma. Prior to her new role Julia pioneered Systems Toxicology Based Approaches for Risk Assessment of consumer products at Philip Morris International. She holds a doctoral degree in molecular biology from Cambridge University in the U.K., an MS in bioinformatics from Georgia Tech in the USA, and an MBA from Business School Lausanne.

Geraldine is the Chief Scientific Officer of Vectura Fertin Pharma and responsible for scientific excellence and scientific governance. She chairs the Vectura Fertin Pharma development committee and acts as the liaison for Vectura Fertin Pharma’s Scientific Advisory Board. Previously Chief Scientific Officer and EVP Pharmaceutical Development at Vectura and Skyepharma, she also held scientific roles at Nektar, Vandsons, and Norton Healthcare, and has been associate professor of pharmacy at VCU. Geraldine is a pharmacist with a PhD in pharmaceutics from University of London. She has a 30-year career in inhaled product development.